Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells

Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, 80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent tumors in 12-33 months after treatment with a median overall survival time of 1-2 years after relapse. LNCaP is a comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hui-Ping, Lin, Ching-Yu, Hsiao, Ping-Hsuan, Wang, Horng-Dar, Sheng Jiang, Shih, Hsu, Jong-Ming, Jim, Wai-Tim, Chen, Marcelo, Kung, Hsing-Jien, Chuu, Chih-Pin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857776/
https://www.ncbi.nlm.nih.gov/pubmed/24349321
http://dx.doi.org/10.1371/journal.pone.0082625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857776/
https://www.ncbi.nlm.nih.gov/pubmed/24349321
http://dx.doi.org/10.1371/journal.pone.0082625

Ejemplares similares